{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:42:03Z","timestamp":1794624123635,"version":"4.9.1"},"reference-count":33,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Am J Sports Med"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Matrix-based cell therapy improves surgical handling, increases patient comfort, and allows for expanded indications with better reliability within the knee joint. Five-year efficacy and safety of autologous cultured chondrocytes on porcine collagen membrane (MACI) versus microfracture for treating cartilage defects have not yet been reported from any randomized controlled clinical trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To examine the clinical efficacy and safety results at 5 years after treatment with MACI and compare these with the efficacy and safety of microfracture treatment for symptomatic cartilage defects of the knee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design:<\/jats:title>\n                    <jats:p>Randomized controlled trial; Level of evidence, 1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This article describes the 5-year follow-up of the SUMMIT (Superiority of MACI Implant Versus Microfracture Treatment) clinical trial conducted at 14 study sites in Europe. All 144 patients who participated in SUMMIT were eligible to enroll; analyses of the 5-year data were performed with data from patients who signed informed consent and continued in the Extension study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 144 patients randomized in the SUMMIT trial, 128 signed informed consent and continued observation in the Extension study: 65 MACI (90.3%) and 63 microfracture (87.5%). The improvements in Knee injury and Osteoarthritis Outcome Score (KOOS) Pain and Function domains previously described were maintained over the 5-year follow-up. Five years after treatment, the improvement in MACI over microfracture in the co-primary endpoint of KOOS pain and function was maintained and was clinically and statistically significant ( P = .022). Improvements in activities of daily living remained statistically significantly better ( P = .007) in MACI patients, with quality of life and other symptoms remaining numerically higher in MACI patients but losing statistical significance relative to the results of the SUMMIT 2-year analysis. Magnetic resonance imaging (MRI) evaluation of structural repair was performed in 120 patients at year 5. As in the 2-year SUMMIT (MACI00206) results, the MRI evaluation showed improvement in defect filling for both treatments; however, no statistically significant differences were noted between treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Symptomatic cartilage knee defects 3 cm\n                      <jats:sup>2<\/jats:sup>\n                      or larger treated with MACI were clinically and statistically significantly improved at 5 years compared with microfracture treatment. No remarkable adverse events or safety issues were noted in this heterogeneous patient population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0363546518756976","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T15:26:16Z","timestamp":1521732376000},"page":"1343-1351","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":291,"title":["Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Five-Year Follow-up of a Prospective Randomized Trial"],"prefix":"10.1177","volume":"46","author":[{"given":"Mats","family":"Brittberg","sequence":"first","affiliation":[{"name":"Cartilage Research Unit, University of Gothenburg, Region Halland Orthopaedics, Kungsbacka Hospital, Kungsbacka, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Recker","sequence":"additional","affiliation":[{"name":"Vericel Corporation, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ilgenfritz","sequence":"additional","affiliation":[{"name":"Independent Consultant, Coconut Grove, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.F.","family":"Saris","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht, Utrecht, the Netherlands"},{"name":"Reconstructive Medicine, Tissue Regeneration, MIRA Institute, University of Twente, Enschede, the Netherlands"},{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SUMMIT Extension Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"bibr1-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.87B3.15552"},{"key":"bibr2-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1007\/s00590-006-0096-x"},{"key":"bibr3-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.87B5.15905"},{"key":"bibr4-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1007\/s00167-009-1028-1"},{"issue":"13","key":"bibr5-0363546518756976","first-page":"194","volume":"2006","author":"Behrens P","journal-title":"Knee"},{"key":"bibr6-0363546518756976","doi-asserted-by":"crossref","unstructured":"Briggs KK, Rodkey WG, Steadman J. The effect of lesion size on clinical outcome after microfracture. Osteoarthritis Cartilage. 2013;21(suppl):S117. http:\/\/dx.doi.org\/10.1016\/j.joca.2013.02.249. Accessed November 18, 2017.","DOI":"10.1016\/j.joca.2013.02.249"},{"key":"bibr7-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546509346395"},{"key":"bibr8-0363546518756976","unstructured":"Brittberg M, Saris D, Price A, Yu Q, Kili S, Brittberg M. Poster 169. SUMMIT Extension: matrix-induced autologous chondrocyte implant vs microfracture at three years. http:\/\/aaos2015.conferencespot.org\/58906-aaos-1.1965581\/t002-1.1973805\/f002-1.1973806\/a013-1.1974529\/p169-1.1974602. Accessed March 31, 2017."},{"key":"bibr9-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143420"},{"key":"bibr10-0363546518756976","doi-asserted-by":"publisher","DOI":"10.2519\/jospt.1998.28.4.192"},{"key":"bibr11-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546513510140"},{"key":"bibr12-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546510390476"},{"key":"bibr13-0363546518756976","unstructured":"EMA reflection paper on in-vitro cultured chondrocyte containing products for cartilage repair of the knee (EMA\/CAT\/CPWP\/568181\/2009). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/05\/WC500090887.pdf. Accessed October 11, 2017."},{"key":"bibr14-0363546518756976","unstructured":"FDA Guidance for Industry. Preparation of IDEs and INDs for products intended to repair or replace knee cartilage. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/CellularandGeneTherapy\/UCM288011.pdf. Published December 2011."},{"key":"bibr15-0363546518756976","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-5-200009050-00007"},{"key":"bibr16-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1302\/0301-620X.91B8.21824"},{"key":"bibr17-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/1947603516638901"},{"key":"bibr18-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546505281918"},{"key":"bibr19-0363546518756976","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-200710000-00002"},{"key":"bibr20-0363546518756976","doi-asserted-by":"publisher","DOI":"10.2106\/00004623-200403000-00001"},{"key":"bibr21-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546517701912"},{"key":"bibr22-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546512457008"},{"key":"bibr23-0363546518756976","doi-asserted-by":"publisher","DOI":"10.3310\/hta21060"},{"key":"bibr24-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546508328414"},{"key":"bibr25-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1016\/j.arthro.2014.11.023"},{"key":"bibr26-0363546518756976","first-page":"B137","volume":"15","author":"Rapko S","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"key":"bibr27-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1016\/S1063-4584(07)61547-7"},{"key":"bibr28-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546514528093"},{"key":"bibr29-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/1947603514562064"},{"key":"bibr30-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1016\/S1048-6666(97)80033-X"},{"key":"bibr31-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1177\/0363546511422220"},{"key":"bibr32-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1007\/s00264-016-3391-0"},{"key":"bibr33-0363546518756976","doi-asserted-by":"publisher","DOI":"10.1016\/j.arthro.2015.09.010"}],"container-title":["The American Journal of Sports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0363546518756976","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0363546518756976","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0363546518756976","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:51:52Z","timestamp":1777369912000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0363546518756976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1177\/0363546518756976"],"URL":"https:\/\/doi.org\/10.1177\/0363546518756976","relation":{},"ISSN":["0363-5465","1552-3365"],"issn-type":[{"value":"0363-5465","type":"print"},{"value":"1552-3365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]}}}